SAB Biotherapeutics, Inc. $SABS Position Lifted by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP grew its stake in shares of SAB Biotherapeutics, Inc. (NASDAQ:SABS) by 47.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 736,077 shares of the company’s stock after acquiring an additional 236,077 shares during the period. Seven Fleet Capital Management LP owned about 0.81% of SAB Biotherapeutics worth $2,871,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. PNC Financial Services Group Inc. acquired a new stake in shares of SAB Biotherapeutics in the 1st quarter valued at about $29,000. ADAR1 Capital Management LLC acquired a new position in SAB Biotherapeutics in the third quarter worth about $30,000. Dimensional Fund Advisors LP acquired a new position in SAB Biotherapeutics in the third quarter worth about $32,000. State of Wyoming bought a new stake in SAB Biotherapeutics in the fourth quarter valued at about $34,000. Finally, Virtu Financial LLC bought a new stake in SAB Biotherapeutics in the third quarter valued at about $40,000. Institutional investors own 7.82% of the company’s stock.

Wall Street Analyst Weigh In

SABS has been the topic of a number of research analyst reports. Rodman & Renshaw reaffirmed a “buy” rating and set a $13.00 target price on shares of SAB Biotherapeutics in a report on Monday, May 11th. Citigroup initiated coverage on SAB Biotherapeutics in a report on Friday, May 22nd. They issued a “buy” rating and a $11.00 price target for the company. Chardan Capital raised their price objective on SAB Biotherapeutics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Wednesday, June 17th. Jefferies Financial Group initiated coverage on shares of SAB Biotherapeutics in a report on Wednesday, May 20th. They issued a “buy” rating and a $11.00 price objective for the company. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of SAB Biotherapeutics in a research note on Monday, June 15th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $12.00.

SAB Biotherapeutics Price Performance

Shares of SAB Biotherapeutics stock opened at $3.72 on Friday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.01. The business’s 50 day simple moving average is $3.74 and its 200-day simple moving average is $3.77. The stock has a market capitalization of $338.48 million, a price-to-earnings ratio of -2.86 and a beta of 0.53. SAB Biotherapeutics, Inc. has a twelve month low of $1.85 and a twelve month high of $5.15.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.28) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.28). Equities research analysts forecast that SAB Biotherapeutics, Inc. will post -1.17 earnings per share for the current year.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.